Completed × Urinary Bladder Neoplasms × Breast × Clear all
NCT05461430 2026-04-13

TraveraRTGx

Travera Inc

Completed
72 enrolled
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT03301493 2025-04-10

Genomic Testing and Resulting Medical Decisions

Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed
1,500 enrolled
NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
37 enrolled
NCT03154190 2025-01-24

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Stanford University

Phase NA Completed
128 enrolled 24 charts
NCT04028479 2024-12-18

ROOT

Taproot Health

Completed
167 enrolled
NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
NCT04604158 2024-05-21

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Cedars-Sinai Medical Center

Phase NA Completed
38 enrolled
NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Corvus Pharmaceuticals, Inc.

Phase 1 Completed
117 enrolled
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
NCT00002520 2023-06-15

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

Eastern Cooperative Oncology Group

Phase NA Completed
434 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT00101972 2022-02-22

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

MacroGenics

Phase 1 Completed
53 enrolled
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 3 FDA
NCT00066404 2020-05-13

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT00477919 2019-05-15

E-MOSAIC Electronic Tool to Monitor Symptoms

Swiss Cancer Institute

Completed
264 enrolled
NCT00253708 2017-08-07

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

Beth Israel Deaconess Medical Center

Phase NA Completed
39 enrolled 15 charts
NCT01015963 2017-07-13

Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871

Alliance for Clinical Trials in Oncology

Completed
69 enrolled